Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-expressing Gynecological Malignancies
NCT04965519Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in Cervical Cancer (CC), ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), endometrial cancer (EC), sponsored by RemeGen. Started Dec 2021; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Cervical Cancer (CC)ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04965519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965519.